Zoetis Announces Appointment Of Glenn David As Acting Chief Financial Officer
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, senior vice
president of Finance Operations, has been named acting Chief Financial
Officer (CFO), and will assume responsibility for the oversight of the
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, senior vice president of Finance Operations, has been named acting Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company’s financial management and global operations, effective immediately. David will succeed Executive Vice President and Chief Financial Officer Richard (Rick) Passov, who will be leaving the company at the end of April. “Glenn is a tenured, well-respected leader in our organization,” said Chief Executive Officer Juan Ramón Alaix. “His deep financial experience and knowledge of the animal health business has been serving Zoetis well, and I have every confidence in his ability to steward our financial operations at this time.” With David in place as acting CFO, reporting to Alaix, the company indicated it will commence a search process among internal and external candidates for the chief financial officer position. Experienced and Knowledgeable Finance Leader With more than 20 years of experience in finance and operations – including roles at Pfizer, Bankers Trust, Paine Webber and Credit Suisse – David has played a key role in leading the financial operations for Zoetis since its Initial Public Offering (IPO), including financial planning, analysis and support across its 70 global markets. Most recently, David has served as senior vice president of Finance Operations for Zoetis, where he had led a team of more than 300 finance professionals and played a critical role in the company’s preparation and execution of its IPO in 2013. Before the Zoetis IPO, David enjoyed a career in Finance at its former parent company, Pfizer. He served in various financial roles at Pfizer, including vice president of Global Finance for Pfizer Animal Health and vice president of Finance for the U.S. Primary Care franchise. David also played important financial roles in Pfizer’s integrations of the Pharmacia, Wyeth and King Pharmaceuticals’ acquisitions.